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ABSTRACT
Tandem autotransplants are used to treat advanced testis cancer patients but their value compared to a single
autotransplant is unknown. To evaluate the results of autotransplant in relapsed testicular/germ cell cancer,
data from 300 patients undergoing autotransplants 1989-2002 were reported to the Center for International
Blood and Marrow Transplant Research. We compared results for those patients intended to undergo tandem
autotransplant procedures (N  102) versus patients in whom a second autotransplant was not planned (N 
198). Five-year survival probability was 35% (95% confidence interval  25%-46%) in the planned tandem
transplant cohort compared to 42% (35%-49%) in the group not planned to have a second transplant (P .29).
Probability of progression-free survival at 5 years for these cohorts was 34% (25%-44%) and 38% (31%-45%),
respectively (P  .50). The planned tandem autotransplant cohort had significantly more advanced disease at
diagnosis and greater likelihood of cisplatin resistance. Patients intended to receive tandem transplants had a
lower treatment-related mortality at 1 year (3% versus 10%, P  .02). Using propensity score analysis the
planned tandem autotransplant cohort had significantly lower treatment-related mortality (P  .044) but no
different risk of relapse (P  .541) compared to the planned single transplant cohort. Tandem autotransplants
for testicular cancer are associated with less treatment-related mortality than a planned single transplant, with
no differences in disease-related outcomes or overall survival at 3 years. Patient selection bias for either
transplant approach, however, may affect the results of this observational study; a randomized trial is needed
to determine which approach, if either, is better.
© 2007 American Society for Blood and Marrow Transplantation
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[NTRODUCTION
Conventional combination chemotherapy with or
ithout surgical resection is curative in nearly 80% of
estis cancer patients, and about 1/4 of relapsed pa-
ients are cured using cisplatin and ifosfamide-con-
aining regimens [1-3]. Poor-prognosis germ cell can- t
78er patients can be identiﬁed for whom the 5-year
urvival rates are considerably less than 50% [4,5];
everal approaches have been used to improve out-
ome in these high-risk patients, including increasing
ose intensity and alternating chemotherapy regimens
6-8]. Autologous hematopoietic stem cell transplan-
ation (HSCT) has been utilized as therapy for pa-
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Tandem Autotransplants in Testis Cancer 779ients with refractory and relapsed testis and germ cell
ancer and as ﬁrst-line therapy for poor-risk patients
9-12]. The optimal timing of transplantation and
actors predicting survival are controversial. In 1996,
eyer et al. [13] reported prognostic factors for pa-
ients with testicular cancer receiving single autolo-
ous HSCT. Cisplatin resistance, primary medias-
inal cancers, progressive disease before autologous
SCT, and serum beta human chorionic gonado-
rophin (-HCG) 1000 mU/mL before transplan-
ation were adverse prognostic factors [13]. To im-
rove results of autologous HSCT, many centers
egan using 2 consecutive or tandem autotransplant
rocedures rather than single autotransplants [14-
6]. Despite the lack of efﬁcacy data, it has been
stimated that 30% of such patients undergo tandem
utotransplants. Using data reported to the Center for
nternational Blood and Marrow Transplant Research
CIBMTR) we studied outcomes after autologous
SCT for testicular cancer between January 1, 1989,
nd December 31, 2001, to determine the value of
lanned tandem (n  102) versus planned single (n 
98) autotransplants.
ATIENTS AND METHODS
ata Sources
The CIBMTR is a research afﬁliation of the Inter-
ational Bone Marrow Transplant Registry (IBMTR),
utologous Blood and Marrow Transplant Registry
ABMTR), and the National Marrow Donor Program
NMDP) that comprises a voluntary working group of
ore than 450 transplantation centers worldwide.
hese centers contribute detailed data on consecutive
llogeneic and autologous HSCT to the Statistical
enter at the Medical College of Wisconsin in Mil-
aukee or the NMDP Coordinating Center in Min-
eapolis. Participating centers are required to report
ll transplants consecutively; compliance is monitored
y on-site audits. Patients are followed prospectively,
ith yearly follow-up.
All CIBMTR teams contribute registration data
hat include disease type, age, sex, pretransplant dis-
ase stage, and chemotherapy responsiveness, date of
iagnosis, graft type (bone marrow, blood-derived
tem cells, or cord blood), pretransplant conditioning
egimen, posttransplant disease progression and sur-
ival, development of a new malignancy, and cause of
eath. Research data are collected on selected subsets
f registered patients and include comprehensive pre-
nd posttransplant clinical information.We developed
nd used a testis cancer-speciﬁc data collection form
hat included known prognostic factors for outcome,
omputerized checks for errors, physician reviews of
ubmitted data, and on-site audits of participating
enters ensure the quality of data. Based on data col- dected in the Centers for Disease Control Hospital
urveys [17,18] and the U.S. Government Accounting
fﬁce [19,20] and worldwide surveys of transplant
ctivity, approximately 40% of allogeneic transplants
orldwide and more than 50% of autotransplants in
orth and South America are registered with the
IBMTR.
atients
Between January 1, 1989, and December 31, 2001,
21 patients who received autotransplants for testicu-
ar cancer were reported to the CIBMTR and had
omplete research data. Twenty-one patients were
xcluded from further analyses because of histology
12 pure teratoma and 5 pure yolk sac) and because the
rimary origin site was mediastinal (4); 300 patients
ere analyzed. The identiﬁed cases came from 76
eporting centers in 8 different countries. The largest
ransplant center has 18 patients. Participating centers
ere contacted to conﬁrm attribution of second trans-
lant as: “planned tandem” or delivered for recurrent
isease that was “not planned”; and to determine
hether there were patients for whom a second trans-
lant was planned but not executed. To assure that the
esearch patients were representative of all registered
atients, demographics and survival rates between
esearch and registered patients were compared; no
ifferences were noted in age, gender, number of
ransplants, graft type, interval from diagnosis to
ransplant, and overall survival (OS). Median fol-
ow-up of survivors after autologous HSCT was 62
range: 2-163) months.
tudy Endpoints
Primary outcomes studied were treatment-related
ortality (TRM), cancer progression or relapse, pro-
ression-free survival, and OS. TRM was deﬁned as
eath in the ﬁrst 28 days after transplant or death
eyond 28 days after transplant in the absence of
ecurrence or cancer progression. Patients alive and in
ontinuous complete remission were censored at the
ime of last follow-up. PFS was deﬁned as survival
ithout recurrence or cancer progression, as mea-
ured by exam, radiographs, and/or an increase in
erum cancer markers. Recurrence or progression of
isease and death from any cause were considered
vents. Those who survived without recurrence or
rogression were censored at the date of last contact.
S was deﬁned as the interval between transplant and
eath from any cause. Surviving patients were cen-
ored at the date of last contact. Disease-risk (favor-
ble, intermediate, poor risk) was based on disease
haracteristics [13] as well as blood cancer markers at
iagnosis [21].
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H. M. Lazarus et al.780tatistical Analysis
Comparisons of descriptive factors were performed
sing chi-square testing for discrete covariates, and the
ruskal-Wallis test for continuous covariates. Univariate
robabilities of TRM and relapse/progression were
omputed using cumulative incidence to accommodate
ompeting risks. Relapse/progression is the competing
isk for TRM and TRM is the competing risk for re-
apse/progression [22]. Univariate probabilities of PFS
nd OS were computed using the Kaplan-Meier method
21]. Estimates of standard error for the survival function
ere calculated by Greenwood’s formula and 95% con-
dence intervals (CI), using log-transformed intervals.
tatistical Methods
A propensity score approach was used to compare
andem and single autologous HSCT while adjusting
or the varying patient risk factors [23,24]. First, the
ikelihood of being assigned to the planned tandem
rm was modeled with patient, disease, and treatment-
elated variables using logistic regression. Predicted
robabilities of being in the planned tandem arm were
omputed and used to group patients into 5 strata.
ultivariate Cox proportional hazards regression with
main effect of treatment group, stratiﬁed on propen-
ity score group, and including additional transplant-
elated covariates, were used to adjust for other po-
able 1. Variables Tested in Logistic Regression Model for Likelihood o
core Analysis (Cox with Propensity Score)
ogistic regression model:
Patient-related variables:
Age at transplant: <30 years* versus >30 years
Karnofsky performance status at transplant: <90%* versus >
Disease-related variables at diagnosis:
Histology: pure seminoma* versus nonseminoma versus mix
Risk: nonseminoma poor risk* versus others versus missing
Alpha-fetoprotein: good risk* versus intermediate risk versus
HCG: good risk* versus intermediate risk versus poor risk ve
Disease-related variables prior to transplant:
Number of conventional chemotherapy regimens: 1* versus
Number of total chemotherapy cycles: 1-5* versus 6-10 versu
Prior salvage attempts: 0* versus 1 versus 2 versus 3
Sensitivity to last platinum-containing regimen: CR  PR* ve
Sensitivity to last platinum containing regimen: CR* versus P
Disease status prior to first transplant: no evidence of diseas
elevation only versus residual cancer with elevated serum
Time from diagnosis to first transplant: <12 months* versus
Treatment-related:
Year of transplant: 1989-1996* versus 1997-2001
ropensity score analysis:
Main effect variable
Intended number of transplants: No planned second transpla
Disease-related variables prior to transplant:
Conditioning regimen, first transplant: carboplatin  VP16 
ifosfamide versus others
Conditioning regimen dose intensity: Carboplatin >2000 mg
Treatment-related:
Source of stem cells: BM* versus PBSC versus BM  PBSCentially confounding risk factors. A comparison
etween tandem and single autologous HSCT was
erformed as an intention-to-treat (ITT) analysis.
he assumption of proportional hazards for each fac-
or in the Cox model was tested using time-dependent
ovariates. When this indicated differential effects
ver time (nonproportional hazards), models were
onstructed breaking the posttransplant time course
nto 2 periods, using the maximized partial likelihood
ethod to ﬁnd the most appropriate breakpoint.
irst-order interactions between main effect and strata
r signiﬁcant covariates were tested before and after
tepwise modeling. After modeling time-varying ef-
ects and interactions, the ﬁnal multivariate model was
uilt using a forward stepwise model building ap-
roach to develop models for TRM, relapse/progres-
ion, PFS, and OS, forcing the main effect into the
odel and stratifying on propensity score strata. Fac-
ors signiﬁcantly associated with the outcome at a 5%
evel (2-sided) were kept in the ﬁnal model. The vari-
bles tested in the logistic regression model for the
ikelihood of receiving a planned second transplant
nd the variables tested in the Cox regression analysis
tratiﬁed on propensity score are listed in Table 1 . An
dditional subgroup analysis was performed on the
roup of patients with residual cancer and elevated
erum cancer markers before transplantation who are
ing a Planned Second Transplant (Propensity Score) and Propensity
inoma  nonseminoma
risk versus missing
issing
s >3
versus missing
hers versus missing
us others versus missing
r surgically or clinically defined* versus serum cancer marker
markers versus residual cancer with normal markers
onths
sus planned second transplant (intention to treat)
ersus carboplatin  VP16 versus carboplatin  VP16 
Etoposide >2200 mg/m2 (high dose) versus others (low dose)f Receiv
90%
ed sem
poor
rsus m
2 versu
s >11
rsus ot
R vers
e, eithe
cancer
>12 m
nt* ver
CY* v
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Tandem Autotransplants in Testis Cancer 781t high risk of relapse. Univariate Cox regression
odels as described above were used to estimate the
elative risk of relapse for these high risk patients in
he tandem versus single autologous transplant
roups. There were no statistically signiﬁcant center
ffects [25].
ESULTS
Three hundred patients were analyzed; 198
lanned to receive single, whereas 102 patients
lanned to receive tandem autotransplants (Table 2).
he cohorts were comparable for median age, pro-
ortion with performance status 90% at transplant,
esticular versus abdominal origin, histology, risk [16],
erum -protein and -HCG [26] at diagnosis, serum
-HCG at time of ﬁrst transplant [13], number of
hemotherapy regimens prior to HSCT, and interval
rom diagnosis to ﬁrst HSCT. For the planned single
ersus the planned tandem transplant groups, 20%
nd 14% of patients had no evidence of cancer when
hey received the ﬁrst transplant, and an additional
% and 4% had only serum cancer marker elevation at
ransplant, respectively. Seventy-one percent and 82%
f patients had residual cancer at time of HSCT,
espectively. The planned tandem transplant cohort
as signiﬁcantly more likely to receive blood rather
han marrow as the stem cell source; however, using
he propensity score adjusted Cox model, source of
tem cells was not a factor. Further, there also was no
ifference in the groups for year of HSCT. Impor-
antly, the tandem cohort had a signiﬁcantly higher
roportion of patients with adverse risk features in-
luding more advanced disease stage at diagnosis (tes-
icular and retroperitoneal node involvement) and cis-
latin-resistance at time of transplantation. Other
omorbidities reported by the teams to the Registry
ncluded cardiovascular disease, gastrointestinal disor-
ers, hepatic dysfunction, and pulmonary disease.
hese conditions were evenly distributed between the
atient groups (data not shown). A higher percentage
f the planned tandem autologous HSCT patients
eceived a carboplatin and etoposide conditioning reg-
men rather than the drug regimen used more often
or single transplants. We tested the conditioning reg-
men dose and dose intensity in the propensity score
djusted Cox model but found these factors were not
igniﬁcant. Median follow-up of the groups was 63
range: 5-163) months for the planned single and 53
range: 2-132) months for the planned tandem trans-
lants.
Cumulative incidence of TRM was 10% (95% CI:
%-14%) at 1 year for the planned single transplant
ohort and 3% (95% CI: 1%-7%) for the planned
andem cohort (intent-to-treat, P  .02). Table 3
hows the unadjusted TRM remained higher at 3 and 9years for the planned single transplant patient co-
ort (P .03 and 0.02, respectively). Relapse/progres-
ion incidence was similar for the 2 cohorts. PFS and
S at 1, 3, and 5 years after autotransplant were
imilar (Figures 1 and 2, Table 3). The probability of
FS at 5 years for the planned tandem transplant
ohort was 34% (95% CI, 25%-44%) compared to
8% (31%-45%) in the planned single transplant co-
ort (pointwise P  .50). The probability of 5-year
S was 35% (25%-46%) versus 42% (35%-49%),
espectively, in the 2 transplant groups (P  .29).
one of the 22 patients (15 single- and 7 tandem-
SCT) who received 3 or more salvage attempts before
ransplant became long-term survivors (Table 2 and
igure 2).
Variables from the logistic regression model that
redict likelihood of being in the planned tandem
ransplant cohort included disease state at ﬁrst trans-
lant and disease stage at diagnosis (Table 4). Specif-
cally, patients with residual cancer and elevated serum
ancer markers were more likely to be in the planned
econd transplant group (odds ratio [OR] 2.28, 95%
I  1.09-4.78, P  .029), compared to patients with
o evidence of disease. Also, patients with retroperi-
oneal cancer involvement with or without testis in-
olvement at diagnosis were more likely to be in the
lanned second transplant cohort (OR  3.84, 95%
I  1.59-9.31, P  .003).
In Cox regression analysis stratiﬁed on propen-
ity score (Table 4) the planned tandem autotrans-
lant group had signiﬁcantly lower TRM (P 
044). Propensity score analysis indicated that there
as no statistically signiﬁcant difference in risk of
elapse in the planned tandem transplant group com-
ared to the planned single transplant population (P
54) (Table 4).
Table 4 shows the risk of treatment failure and
verall mortality. The effect of tandem transplanta-
ion on PFS and OS was time dependent. Patients
ho received tandem transplantation had signiﬁcantly
etter PFS within the ﬁrst 9 months after transplant
nd higher OS within the ﬁrst 3 months after trans-
lant compared to those receiving only 1 transplant.
n those who survived beyond these time points, there
as no signiﬁcant difference between the groups.
A subgroup analysis of relapse in the high-risk
residual cancer with elevated serum cancer markers at
ransplant) cohort found a signiﬁcant time-dependent
ffect. There was no signiﬁcant difference in relapse
ithin the ﬁrst 9 months after transplant (RR  0.72,
5% CI  0.46-1.14, P  .16); however, the relapse-
isk was higher in the tandem group in those who
urvived disease free for 9 months after transplant
RR  4.59, 95% CI  1.29-16.35, P  .019).
The overwhelming reason for failure was disease
ecurrence in both cohorts (79% planned single and
4% planned tandem autotransplant), but organ fail-
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H. M. Lazarus et al.782able 2. Characteristics of Patients Receiving Bone Marrow and/or Peripheral Blood Stem Cell Autologous Transplantation for Testicular Cancer
eported to the CIBMTR, from 1989 to 2001, by Intended Number of Transplants
No Planned 2nd tx Planned 2nd tx (ITT)
Variable N Eval N (%) N Eval N (%) P-valueb
umber of patients 198a 102a
ge, median (range), yearsc 198 31 (15-59) 102 30 (17-63) .83
ge at transplant, yearsc 198 102 .15
11-20 20 (10) 12 (12)
21-30 78 (40) 42 (41)
31-40 68 (34) 34 (33)
41-50 30 (15) 9 (9)
>51 2 (1) 5 (5)
arnofsky score pretransplantc 189 100 .74
50 2 (1) 1 (1)
60 2 (1) 2 (2)
70 17 (9) 9 (9)
80 46 (24) 17 (17)
90-100 122 (65) 71 (71)
arnofsky score pretransplant <90c 189 67 (35) 100 29 (29) .27
rigin of primary cancer at diagnosisc 198 102 .51
Testicular primary 183 (92) 92 (90)
Abdominal nodes primary 15 (8) 10 (10)
tage at diagnosis 198 102 .04
Testis primary
Testis only 49 (25) 11 (11)
Testis  retroperitoneal only 23 (12) 22 (21)
Any CNS involvement 9 (4) 4 (4)
Widespread involvement 102 (51) 55 (54)
Extragonadal primary
Retroperitoneal only 2 (1) 2 (2)
Widespread involvement 13 (7) 8 (8)
istology at diagnosisc 193 99 .78
Seminoma  any nonseminoma 31 (16) 20 (20)
Pure seminona 28 (15) 18 (18)
Pure choriocarcinoma 18 (9) 7 (7)
Pure embryonal 24 (12) 9 (9)
Pure (other)d 4 (2) 1 (1)
Mixed nonseminoma (without seminoma) 87 (45) 44 (45)
None 1 (1) 0
isk at diagnosisce 191 101 .40
Nonseminoma—good risk 40 (21) 13 (13)
Nonseminoma—intermediate risk 27 (14) 13 (13)
Nonseminoma—poor risk 68 (36) 35 (34)
Nonseminoma—not specified 8 (4) 6 (6)
Nonseminoma—none 1 (1) 1 (1)
Seminoma—good prognosis 14 (7) 9 (9)
Seminoma—intermediate prognosis 16 (8) 16 (16)
Seminoma—not specified 8 (4) 6 (6)
None—nonseminoma  seminoma 9 (5) 2 (2)
erum -fetoprotein at diagnosis, (exclude pure seminoma), median
(range), ng/mLcf 110 485 (0-278,455) 61 257 (0-58,649) .19
erum -fetoprotein at diagnosis (exclude pure seminoma)cfg 110 61 .26
Good risk 63 (57) 42 (69)
Intermediate risk 34 (31) 12 (20)
Poor risk 13 (12) 7 (11)
erum -fetoprotein at diagnosis (exclude pure seminoma)cf 110 61 .29
<100,000 ng/mL 108 (98) 61 (100)
>100,000 ng/mL 2 (2) 0
-HCG at diagnosis, median (range), IU/Lch 134 160 (0-140,000) 67 369 (0-113,440) .57
-HCG at diagnosischg 134 67 .63
Good risk 85 (63) 41 (61)
Intermediate risk 28 (21) 12 (18)
Poor risk 21 (16) 14 (21)
-HCG at diagnosisch 134 67 1.00
<100,000 IU/L 130 (97) 65 (97)
>100,000 IU/L 4 (3) 2 (3)
TI
I
N
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S
Tandem Autotransplants in Testis Cancer 783able 2. (Continued)
No Planned 2nd tx Planned 2nd tx (ITT)
Variable N Eval N (%) N Eval N (%) P-valueb
nitial surgeryc 197 102 .66
Orchiectomy only 140 (71) 73 (71)
Unilateral retroperitoneal node dissection and orchiectomy only 13 (7) 11 (11)
Biospsy  other 13 (7) 6 (6)
Debulking only 1 (<1) 1 (1)
Otheri 2 (1) 0
Initial surgery, not specified 2 (1) 0
No initial surgery 26 (13) 11 (11)
nitial chemotherapyc 196 100 .86
VAB 1 (1) 0
PVB 18 (9) 5 (5)
BEP 118 (60) 66 (66)
EP 29 (15) 14 (14)
Other etoposide based regimens 2 (1) 1 (1)
Other vinblastine based therapy 6 (3) 2 (2)
Other chemotherapyj 4 (2) 2 (2)
Chemotherapy given, not specified 2 (1) 0
No chemotherapy 16 (8) 10 (10)
umber of conventional chemotherapy regimens prior to
transplantc 197 102 .20
1 25 (13) 21 (20)
2 101 (51) 55 (54)
3 55 (28) 18 (18)
4 15 (7) 7 (7)
No chemotherapyk 1 (1) 1 (1)
umber of conventional chemotherapy cyclesc 197 102 .14
1-5 46 (23) 33 (32)
6-10 122 (62) 57 (56)
>11 24 (12) 7 (7)
Chemotherapy given, cycles unknown 4 (2) 4 (4)
No chemotherapyl 1 (1) 1 (1)
rior salvage attemptscm (lines after 1st relapse or progression) 198 102 .37
1 82 (41) 39 (38)
2 40 (20) 26 (25)
3 27 (14) 8 (8)
4 2 (1) 0
Others 11 (6) 4 (4)
No salvage attempt 10 (5) 4 (4)
No relapse 25 (13) 19 (19)
First relapse missing 1 (<1) 2 (2)
ensitivity to 1st platinum containing regimencn 191 95 .17
CCR 2 (1) 0
CR 71 (37) 25 (26)
PR 84 (44) 51 (54)
SD 4 (2) 8 (9)
NR 9 (5) 3 (3)
PD 12 (6) 4 (4)
NE 4 (2) 2 (2)
No cisplatin or carboplatin 3 (2) 1 (1)
No chemotherapy 2 (1) 1 (1)
ensitivity to last platinum containing regimenco 184 99 .56
CCR 1 (1) 0
CR 35 (19) 18 (18)
PR 91 (49) 42 (43)
SD 19 (10) 14 (14)
NR 9 (5) 6 (6)
PD 13 (7) 13 (13)
ME 3 (2) 0
NETD 0 1 (1)
NE 8 (4) 3 (3)
No cisplatin or carboplatin 3 (2) 1 (1)
No chemotherapy 2 (1) 1 (1)
TS
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H. M. Lazarus et al.784able 2. (Continued)
No Planned 2nd tx Planned 2nd tx (ITT)
Variable N Eval N (%) N Eval N (%) P-valueb
ensitivity to any platinum-containing chemotherapeutic agent
(as reported by team)c 180 95 <.001
Sensitive 138 (77) 47 (50)
Resistant 31 (17) 42 (44)
Untreated 9 (5) 1 (1)
Refractory 2 (1) 5 (5)
-HCG prior to first transplantc 142 81 .21
<1,000 IU/L 120 (85) 63 (78)
>1000 IU/L 22 (15) 18 (22)
isease status prior to first transplantc 191 99 .011
No evidence of disease surgically defined 9 (5) 2 (2)
No evidence of disease clinically defined 28 (15) 12 (12)
Serum cancer marker elevation only 15 (8) 4 (4)
Residual cancer with elevated markers 71 (37) 59 (60)
Residual cancer with normal markers 65 (34) 22 (22)
Not evaluable 3 (2) 0
isease status prior to second transplantp NA 74 —
No evidence of disease clinically defined 20 (27)
Serum cancer marker elevation only 2 (3)
Residual cancer with elevated markers 28 (38)
Residual cancer with normal markers 20 (27)
Not evaluable 4 (5)
ime from diagnosis to first transplant, median (range), monthsc 198 15 (<1-274) 102 12 (2-257) .06
ime from first to second transplant, median (range), monthsp 2 10 (1-19) 85 1 (1-3) —
ononucleated cells infused, first transplant, median (range), 108/kgc 82 6 (<1-34) 42 4 (<1-39) .38
D34 cells infused, first transplant, median (range), 106/kgcq 90 4 (<1-104) 68 3 (<1-71) .21
onditioning regimen, first transplantr 198 102 <.001
Carboplatin  VP16 34 (17) 45 (44)
Carboplatin  VP16  Ifosfamide 38 (19) 9 (9)
Carboplatin  VP16  CY 91 (46) 32 (31)
Otherss 35 (18) 16 (16)
umber of conditioning drugs, first transplant 198 102 <.001
1 1 (<1) 2 (2)
2 43 (22) 46 (45)
3 146 (74) 54 (53)
4 6 (3) 0
5 2 (1) 0
umber of conditioning drugs, second transplant NA 80 —
0 2 (3)
2 39 (49)
3 38 (47)
4 1 (1)
raft typec 198 102 .009
BM 59 (30) 14 (14)
PBSC 120 (61) 76 (74)
BM  PBSC 19 (9) 12 (12)
lanned 2nd transplant per protocol 198 102 —
1 planned, 1 delivered 196 (99) —
1 planned, 2 delivered 2 (1) —
2nd planned, 1 delivered — 17 (17)
2nd planned, 2 delivered — 85 (83)
umber of transplants 198 102 <.001
1 196 (99) 17 (17)
2 2 (1) 84 (82)
3 0 1 (1)
ear of first transplantc 198 102 .28
1989 4 (2) 0
1990 6 (3) 3 (3)
1991 9 (4) 3 (3)
1992 10 (5) 7 (7)
1993 18 (9) 1 (1)
1994 8 (4) 5 (4)
1995 17 (9) 7 (7)
1996 27 (14) 16 (16)
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No Planned 2nd tx Planned 2nd tx (ITT)
Variable N Eval N (%) N Eval N (%) P-valueb
1997 36 (18) 19 (18)
1998 27 (14) 18 (18)
1999 17 (9) 9 (9)
2000 14 (7) 7 (7)
2001 5 (2) 7 (7)
edian follow-up of survivors, months 198 63 (5-163) 102 53 (2-132) —
x indicates transplant; CCR, continued complete response; CR, complete response; PR, partial response; SD, stable disease; NR, no response;
PD, progressive disease; ME, markers elevated; NETD, not evaluable, toxic death; NE, not evaluable; VAB, cisplatin  carboplatin 
bleomycin  cyclophosphamide  vinblastine; PVB, cisplatin  carboplatin  bleomycin  vinblastine; BEP, bleomycin  etoposide
(VP16)  cisplatin  carboplatin; EP, etoposide  platinum; VP16, etoposide; CY, cyclophosphamide; BM, bone marrow; PBSC,
peripheral blood stem cell; CNS, central nervous system; NA, not applicable; ITT, intention to treat.
FU completeness index  90% (no planned 2nd transplant  90%; planned 2nd transplant (ITT)  89%).
The chi-square test was used for discrete covariates; the Kruskal-Wallis test was used for continuous covariates.
First transplant.
Other histology includes:
Mixed malignant germ cell (n  1).
Mixed germ cell cancer (n  2).
Rhabdomyosarcoma alveolar (n  1).
Unknown (n  1).
Cancers that had a mixture of seminoma and nonseminoma components were classiﬁed as nonseminoma.
Classiﬁcation for good, intermediate, and poor risk:
Nonseminoma:
Good: all of the following: AFP 1000 ng/mL, HCG 5000 IU/L, and LDH 1.5  upper limit of normal; nonmediastinal primary; no
nonpulmonary visceral metastasis.
Intermediate: all of the following: AFP  1000-10,000 ng/mL, HCG  5000-50,000 IU/L, or LDH  1.5-10  upper limit of normal;
nonmediastinal primary site; no nonpulmonary visceral metastasis.
Poor: any of the following: AFP 10,000 ng/mL, HCG 50,000 IU/L, or LDH 10  upper limit of normal; mediastinal primary site;
nonpulmonary visceral metastasis present.
Seminoma:
Good: no nonpulmonary visceral metastasis.
Intermediate: nonpulmonary visceral metastasis present.
There were 63 nonseminoma cases with unknown information.
Mead GM: International consensus prognostic classiﬁcation for metastatic germ cell tumours treated with cisplatinum-based chemotherapy:
ﬁnal report of the International Germ Cell Cancer Collaborative Group (IGCCCG). Proc Am Soc Clin Oncol 1995;14:235. Classiﬁcation
for AFP (ng/mL) and HCG (ng/mL):
Good: 1000 ng/mL.
Intermediate: 1000-10,000 ng/mL.
Poor: 10,000 ng/mL.
There were 64 nonseminoma cases with unknown information.
Other initial surgery were:
B/L RP node (n  1).
Craniotomy/orchiectomy (n  1).
Other chemotherapy were:
Carboplatin  adriamycin (n  1).
Cisplatin  adriamycin (n  1).
Cisplatin  thiotepa (n  1).
Cisplatin alone (n  2).
Cyclophosphamide  gemcitabine (n1).
Patients received:
Initial surgery only (n  1).
Surgery only (n  1).
Patients received:
Initial surgery only (n  1).
Surgery only (n  1).
Median number of salvage attempts: 2.
First line (n  44); second line (n  147); third line (n  73); fourth line (n  21).
Patients who did not received chemotherapy (n 3), cisplatin regimen (n 4), or missing (n 17) were excluded in the multivariate analysis phase.
Second transplant.
There were 38 cases with unknown CD34 information.
10 of 87 patients had a different conditioning regimen for the 2nd transplant.
Other conditioning regimen includes:
Carboplatin  other (n  28).
Others (n  23).
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H. M. Lazarus et al.786re (4%), infection (4%), and hemorrhage (2%) ac-
ounted for many deaths in the planned single auto-
ransplant population.
ISCUSSION
Several early transplant series indicate that a
ingle course of high-dose chemotherapy and autol-
gous HSCT in the management of relapsed or
efractory germ cell cancers could induce durable
omplete remissions (CR) in 23%-34% of patients
t 2 years or beyond with TRM ranging from 3%-
2% [11,16,27,28]. Sophisticated supportive care
echnologies were not routinely available during that
ra; tandem transplants were not considered feasible
ecause of severe mucositis, infection, bleeding, and
enal injury. Nichols et al. [29] reported in 1989 a
igure 1. Adjusted probability of progression-free survival after
utotransplants for testicular cancer, by intended number of trans-
able 3. Univariate Probabilities of Transplant Outcomes among Patie
utologous Transplantation for Testicular Cancer Reported to the CIBM
No Planned 2nd Transplant
Outcome Event N Prob (95% C
RM 195
@ 1 year 10 (6-14)
@ 3 years 11 (7-16)
@ 5 years 11 (7-16)
rogression/relapse 195
@ 1 year 42 (35-49)
@ 3 years 49 (42-56)
@ 5 years 51 (43-58)
FS 195
@ 1 year 48 (41-55)
@ 3 years 40 (33-47)
@ 5 years 38 (31-45)
verall survival 198
@ 1 year 64 (57-70)
@ 3 years 47 (40-54)
@ 5 years 42 (35-49)
RM indicates treatment-related mortality; PFS, progression-free
treat.
Probabilities of treatment-related mortality and progression/relapse
survival and overall survival were calculated using the Kaplan-M
transplant.lants. phase I/II high-dose carboplatin (dose escalation) and
toposide (ﬁxed dose) autologous HSCT study in 33
estis cancer patients who had received at least 2 prior
isplatin-based regimens or were considered cisplatin-
efractory. Seven patients (21%) died from treatment,
nd only 20 patients received tandem autotransplants,
et 4 were long-term disease-free survivors.
The Eastern Cooperative Oncology Group con-
ucted a phase II study using tandem autologous
SCT (carboplatin and etoposide) in 40 patients (22
f 38 evaluable received a second transplant); CCR
as seen in 5 patients [30]. More recently, the group
t Indiana University reported a case series of 65
elapsed germ cell cancer patients (excluding medias-
inal primaries) who received tandem autologous
SCT (carboplatin 2100 mg/m2 and VP-16 2250
g/m2) separated by a period of 4-5 weeks [12]. No
atient in this relatively large series experienced trans-
igure 2. Adjusted probability of overall survival after autotrans-
o Underwent Bone Marrow and/or Peripheral Blood Stem Cell
m 1989 to 2002, by Intended Number of Transplants
Planned 2nd Transplant (ITT)
N Prob (95% CI) P-value*
97
3 (1-7) .02
4 (1-9) .03
4 (1-9) .02
97
53 (43-63) .08
61 (51-70) .06
62 (52-72) .07
97
44 (34-54) .48
35 (26-45) .40
34 (25-44) .50
102
67 (58-76) .54
44 (35-54) .68
35 (25-46) .29
al; PROB, probability; CI, conﬁdence interval; ITT, intention to
alculated using the cumulative incidence estimate. Progression-free
roduct limit estimate. Time to events measured from date of ﬁrstnts Wh
TR, fro
I)
surviv
were c
eier plants for testicular cancer, by intended number of transplants.
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Tandem Autotransplants in Testis Cancer 787lant-related death, and with more than 4 years of
ollow-up, 54% (35 of 65) of patients remain in CCR.
inally, a randomized trial in relapsed advanced germ
ell tumors of 3 cycles of vinblastine, ifosfamide, and
isplatin salvage chemotherapy (VeIP) plus 1 cycle of
igh-dose chemotherapy and autologous HSCT com-
ared with 4 cycles of VeIP showed no survival ben-
ﬁt, suggesting that multiple autotransplants are nec-
ssary to achieve a favorable outcome [31,32]. Results
f these and other series have been considered prom-
sing enough by some transplanters to justify tandem
utologous transplantation.
In the United States, tandem autologous HSCT
sing peripheral blood stem cells (PBSC) appears to
e a common approach. In our series, a signiﬁcant
ercent of patients undergoing planned tandem
able 4. Logistic Regression Model for Likelihood of Receiving a Planne
Factor Level
ogistic regression model:
isease status prior to 1st transplant
No evidence of disease, either surgically or clinically defined
Serum cancer marker elevation only
Residual cancer with elevated markers
Residual cancer with normal markers
Missing
tage
Testis primary—testis only
Retroperitoneal / testis
Widespread involvement or CNS involvement
Variables
ropensity score analyses:
RM*
Intended number of transplants
No planned 2nd transplant
Planned 2nd transplant
rogression/relapse*
Intended number of transplants
No planned 2nd transplant
Planned 2nd transplant
rogression-free survival*
Intended number of transplants
Within first 9 months after transplant
No planned 2nd transplant
Planned 2nd transplant
Beyond first 9 months after transplant
No planned 2nd transplant
Planned 2nd transplant
verall survival*
Intended number of transplants
Within first 3 months after transplant
No planned 2nd transplant
Planned 2nd transplant
Beyond first 3 months after transplant
No planned 2nd transplant
Planned 2nd transplant
R indicates relative risk; CI, conﬁdence interval; OR, odds ratio;
Model stratiﬁed on propensity score strata (5 groups).
*Two degree of freedom test of no difference in risk between planSCT had poorer risk features including more ad- sanced disease at diagnosis and greater likelihood of
xhibiting cisplatin resistance when compared to sub-
ects where 2 autotransplants were not planned. De-
pite these characteristics, patients intended to receive
andem transplants had a signiﬁcantly lower TRM,
% at 1 year compared to 10% in the planned single
ransplant group (P  .02) (Table 4). This low TRM
s similar to the Indiana University published experi-
nce. The intensity of the transplant preparative reg-
mens may partly explain this ﬁnding. Only 53% of
he planned tandem transplant group received a reg-
men containing 3 or more chemotherapeutic agents
n contrast to 78% in the planned single transplant
roup.
Patients who were given a tandem autotransplant
ad a relapse/progression incidence that did not differ
d Transplant and Propensity Score Analyses
N OR (95% CI) P-value
.016
51 1.00
19 0.84 (0.23-3.06) .79
128 2.28 (1.09-4.78) .029
86 0.91 (0.40-2.06) .82
13 0.99 (0.23-4.27) .99
.012
123 1.00
78 3.84 (1.59-9.31) .003
45 2.09 (1.00-4.37) .051
N
RR of Death
(95% CI) P-value
193 1.00
96 0.33 (0.11-0.97) .044
193
96 0.9 (0.64-1.27) .54
.032**
193
96 0.66 (0.46-0.95) .026
193
96 1.63 (0.82-3.21) .16
.038**
196
101 0.24 (0.08-0.72) .01
196
101 0.98 (0.69-1.39) .91
central nervous system.
d no planned second transplant both early and late.d Secon
CNS,igniﬁcantly from the planned single transplant group
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H. M. Lazarus et al.788Table 4). Further, PFS and OS did not differ between
he 2 transplant groups (Figures 1 and 2) after 9
onths from transplant. The probability of survival at
years was approximately 40% for both groups. Re-
apses also appeared to occur infrequently beyond 2
ears after autotransplant. At 1 year after transplant,
4 and 41 patients are at risk of relapse in the single
nd tandem autotransplant arms, and at 2 years there
re 79 and 33 patients, respectively. Nonetheless, the
ajor cause of treatment failure, even in the tandem
utotransplant group, was disease recurrence; 94% of
he deaths in the planned tandem transplant group
nd 79% in the planned single transplant group were
ttributed to cancer recurrence. None of the 22 pa-
ients (15 single and 7 tandem) who received 3 or
ore salvage attempts before transplant became long-
erm survivors. Although these numbers are small,
uch data suggest that this patient subgroup might
est be treated with non-HSCT approaches.
This study has several limitations including the
ccrual of patients during a 12 year period at multiple
nstitutions. Although we used statistical techniques to
djust for differences in patient and disease character-
stics associated with whether a single or tandem au-
ologous HSCT was performed, residual patient se-
ection bias as determined by the transplant centers
ay affect our results. Additionally, prognostic data
n serum cancer markers at presentation was available
or only 60% of patients. Our ﬁnding that high-risk
atients have a greater likelihood of relapse with tan-
em transplantation after 9 months following HSCT
hould be interpreted with caution, as small numbers
f patients were at risk in that time period. We could
ot deﬁnitively determine the role of tandem versus
ingle autologous transplantation because of these
imitations.
Our observational data suggest that planned tan-
em autologous HSCT for testicular cancer have
ower TRM than planned single autotransplants but
imilar long-term outcomes, even though the patients
elected for tandem autotransplant may be at higher
isk for cancer recurrence. Factors considered impor-
ant by transplant centers when selecting patients for
ither approach, however, may not be adequately cap-
ured in an observational database. Our ﬁndings sup-
ort the conduct of a randomized trial to compare
hese 2 approaches. Consideration of the costs of both
ransplant approaches was beyond the scope of this
tudy. There have been no published studies com-
aring costs of different transplant approaches, nor
tudies that consider costs of transplantation com-
ared to alternative salvage treatments. This limi-
ation may further justify conduct of a well-de-
igned clinical trial that includes cost analysis.
Other strategies to improve long-term cancer con-
rol also include sequential conventional chemother-
py and subsequent autotransplant. One group re- Wently reported that repetitive cycles of etoposide,
fosfamide, and cisplatin chemotherapy followed im-
ediately by high-dose chemotherapy and autotrans-
lant as initial therapy for advanced germ cell cancer
rovided a 73% 5-year OS rate, 76% for gonadal and
etroperitoneal versus 67% for mediastinal primaries
28]. Earlier intervention using autotransplant or in-
tituting new regimens that demonstrate antitumor
ctivity with acceptable toxicity, such as gemcitabine
nd oxaliplatin [33], in heavily pretreated patients,
ossibly even in the posttransplant setting, may pre-
ent recurrences. These and other phase I/II data
eed conﬁrmation, although a number of regimens
hat showed promise in single-arm studies failed to
how superior efﬁcacy in phase III trials [32].
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